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INTRODUCTION 
Nowadays the mortality and morbidity due to communicable disease has come 
down, and a striking increase of non communicable disease is due to life style changes 
and urbanization.  
Now the Globe is facing the global epidemic of chronic kidney disease. 
Chronic kidney disease is the one unique amongst the non communicable disease. 
By definition, chronic kidney disease is kidney damage lasting for more than 3 
months and evidenced by either structural or functional abnormalities of the kidney with 
or without  reduction in glomerular filtration rate (GFR). Chronic renal failure is the older 
terminology of chronic kidney disease. The term “renal” replaced by “kidney” to make it 
more patient friendly. 
The term “End stage renal disease”( ESRD) is also changed to chronic kidney 
disease stage 5. 
Vitamin D is a fat soluble organic micro nutrient,through its classical and non-
classical functions improve the clinical outcome of CKD patients. 
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VITAMIN D 
 
 Vitamins are a group of organic micro nutrients. They are essential for a variety of 
biochemical functions. Vitamins are broadly classified into fat soluble vitamins and water 
soluble vitamins.  
 
 Fat soluble vitamins are hydrophobic substances, can be absorbed efficiently only 
when there is normal fat absorption.  
 
 Vitamin D is a Lipid soluble vitamin, strictly speaking, vitamin D is not at all a 
vitamin, it is really a steroid hormone.  
 
 The terminology “vitamin D” denotes a group of closely related sterols produced 
by the action of ultra violet light on specific pro-vitamins.  
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SYNTHESIS AND CHEMISTRY OF VITAMIN D 
 
Vitamin D3 is produced in the skin of mammals from 7– dehydrocholesterol by 
sunlight. The reaction sequence involves the rapid formation of previtamin D3.  
 
Previtamin D3 converted to vitamin D3. Vitamin D3 and its hydroxylated 
derivatives are then carried in the circulation by binding to a globulin which is known as  
vitamin D- binding protein.  
 
 The affinity of vitamin D – binding protein for vitamin D3 is high, so it 
moves vitamin D3 from the skin into circulation. Under most conditions, sunlight is the 
major source of Vitamin D, when the sunlight exposure is inadequate, then dietary source 
is required.  
 
 Vitamin D3 is metabolized by cytochrome P450 (CYP) superfamily 
enzymes. 
 
In the liver, vitamin D3 is converted to 25-Hydroxycholecalciferol (calcidol, 25-OHD3) 
by mitochondrial and microsomal CYP 450 enzymes.   
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FORMATION AND HYDROXYLATION OF VITAMIN D3 
 
FIGURE 1: 
 
 
25-Hydroxy vitamin D3 [25 (OH) D3], is the major circulating and storage form 
of Vitamin D3.  
  
 The half life of 25 (OH) D3 is approximately two to three weeks.  
 
 The second hydroxylation, that is required for the formation of the mature 
hormone, occurs in kidneys.  
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 This 25- hydroxycholecalciferol converted in  the kidneys to more active 
metabolite 1, 25-dihydroxy cholcalciferol, known as calcitriol (or) 1, 25 (OH)2 D3. This 
hydroxylation mediated by 25-hydroxy vitamin D3-1-α  hydroxylase.  The normal 
plasma level of 25-hydroxy cholecalciferol is 30ng/ml, and normal valve of 1, 25 
dihydroxycholecalciferol is around 0.03ng/ml. 
 
 Another less active metabolite that is also formed in the kidneys is 24,25 – 
dihydroxycholecalciferol.  
 
 Vitamin D3 and the derivatives of vitamin D3 are called as secosteroids.  
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SYNTHESIS AND ACTIVATION OF VITAMIN D 
   
FIGURE:2 
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SCHEMATIC REPRESENTATION OF HORMONAL CONTROL LOOP 
FOR VITAMIN D FUNCTION AND METABOLISM 
  FIGURE:3 
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Actions of Vitamin D 
 
 1, 25 (OH)2 D3 regulates its biologic actions by binding to vitamin D receptors.   
 
 The affinity of VDR for 1, 25 (OH)2 D3 is approximately three orders of 
magnitude higher than that of other Vitamin D metabolites.  
 
 The VDR binds to target DNA sequences as a heterodimer with retinoid X – 
receptors, results in the induction of target gene expression.  
 
 This VDR is expressed in wide range of cells and tissues. By inducing calbindin 
9k, TRPV5 and TRPV6  in the small bowel  1,25 (OH)2 D3 increases the efficiency of 
intestinal calcium absorption.  
 
 1, 25- dihydroxycholecalciferol facilitates Ca2+ reabsorption in the renal tubules. 
By the  action on bone, it mobilizes bony Ca2+,  PO43-  by increasing the number of 
mature osteoclasts.  
 
 VDR is expressed in the parathyroid gland and vitamin D3 have antiproliferative 
effect on Parathyroid cells and to suppress the transcription of the parathyroid hormone 
gene. These effects of Vitamin D3 on parathyroid gland are an important part of the 
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rationale for current therapies directed at preventing and treating hyperparathyroidism 
associated with renal insufficiency.  
 
 Vitamin D3 has an anti proliferative effect on keratinocytes breast cancer cells and 
prostate cancer cells.  
 
Vitamin D Deficiency  
 
Is prevalent throughout the globe.  
 
The clinical syndrome of hypovitaminosis D is due to  
 
1) Deficient production of Vitamin D in the skin  
2) Lack of dietary intake.  
3) Accelerated losses of vitamin D.  
4) Impaired vitamin D activation  
5) Resistance to the biologic effects of 1,25 (OH)2 D3 
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Functional anatomy of kidney 
Kidneys are two reddish brown organs, that are situated high up in  posterior abdominal 
wall. 
 The right kidney is slightly lower than the left kidney because of large right lobe of liver. 
During respiration both kidneys are move downwards in a vertical direction by as much 
as 2.5 cm due to contraction of diaphragm. 
A vertical slit on the medial border of each kidney is bounded by thick lips of renal 
substance is called hilum. The hilum extends into a large cavity known as renal sinus. 
The hilum transmits, the renal vein, the two branches of renal artery,the ureter, the third 
branch of renal artery from the front backward. It also transmits lymph vessels and 
sympathetic fibers. 
Coverings  of the kidney  
1) Fibrous capsule. 
2) Perirenal fat. 
3) Renal fascia. 
4) Pararenal fat. 
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Posterior abdominal wall showing the kidneys 
FIGURE:4 
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Renal structure 
Each kidney has a dark brown outer cortex and an inner light brown medulla and the 
medulla has a dozen of renal pyramids. Each pyramid has its base oriented towards the 
cortex and its apex,the renal papilla, projecting medially. The renal columns are cortical 
extentions into the medulla between adjacent pyramids.    
The renal sinus, a space in the hilum,consists the upper expanded end of the ureter,renal 
pelvis. 
Renal pelvis divided into 2 to 3 major calyces,which in turn divided into 2 to 3 minor 
calyces. These minor calyx is indented by the apex of the renal papilla. 
FIGURE 5   :  CUT SECTION OF KIDNEY AND NEPHRONS 
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Blood supply of kidney 
Arterial supply 
Kidneys are supplied by the renal arteries arising from the abdominal aorta at the  2nd  
lumbar vertebrae level. Each renal artery divided into five segmental arteries that enter 
the hilum of the kidney and are distributed to different segments or areas of the kidney. 
From each segmental artery the lobar arteries arises one each for renal pyramid. Each 
lobar artery gives 2 to 3 interlobar arteries before they entering the renal substances. The 
interlobar arteries run toward the cortex on both sides of renal pyramid. The arcuate 
arteries arises from the interlobar arteries at the junction of the cortex and medulla arch 
over the bases of the pyramids. The arcuate arteries gives off many interlobular arteries 
that ascend in the cortex. The afferent glomerular arterioles arises from interlobular 
arteries. 
Venous drainage 
Each renal vein emerges from the hilum of the kidney in front of the renal artery and 
drains into the inferior vena cava. 
Nerve supply 
The nerve supply to the kidneys is from the renal sympathetic plexus. The afferent fibers 
from the renal plexus enter the spinal cord in the 10th,11th, and 12th thoracic nerves. 
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Functional anatomy 
Nephrons  are the basic functional unit of the kidney, composed of renal tubule and its 
glomerulus. The size of the kidney is largely determined by the number of nephrons in 
the kidneys. Each human kidney contains about 1.3 million nephrons. 
The glomerulus, which  is formed by  invagination of a tuft of capillaries into the dilated 
blind end of the nephron. The size of the glomerulus is about 200 µm in diameter. 
The capillaries are supplied by an afferent arteriole and drained by an efferent arteriole.  
In the bowmen’s  capsule two cellular layers separating  blood from  glomerular filtrate. 
The two layers are capillary endothelium and specialized capsular epithelium that is made 
up of podocytes. These two layers are separated by a basal lamina. Mesangial cells are a 
type of stellate  cells,which are located between the basal lamina and the endothelial 
cells. Mesangial cells are equivalent of pericytes, which are found in the capillary walls, 
elsewhere in the body. 
The mesangial cells are able to contract naturally  and plays  a vital role in the regulations 
of glomerular function. The mesangial cells also produce many substances, takes  
immune complexes and implicated in  process of glomerular diseases. 
Podocyte  has numerous pseudopodias,which interdigitate and forms the filtration slit 
along the capillary walls.  
  
15 
  
Functionally, glomerular membranes allows  free path of neutral substances up to 4nm 
size and excludes substances with diameter greater than 8nm. The total filtration area of 
glomerular capillary endothelium is about 0.8m2. 
The proximal convoluted tubule in human is  15 mm long and 55µm in width and the 
wall is made up of a single layer of cells which interdigitate with one another and  united 
by apical tight junctions. 
Cortical nephrons which are present in the renal cortex are made up of short loop of 
henle. 
Juxtamedullary nephrons which are present in the juxtamedullary region of the cortex are 
made up of long loops extending down into the  pyramids. In human beings 15% of the 
nephrons have long loops. 
The length of thin segment of the loop, varies from 2 to 14 mm and it ends with thick 
segment of the ascending limb, which is about 12 mm in length. The cells of thick 
ascending limb are cuboidal and have numerous mitochondria. The thick ascending limb 
reaches the glomeruli from there the tubule arose and passes close to its afferent and 
efferent arteriole. The afferent arteriole wall contain renin- secreting juxtaglomerular 
cells. Here the tubular epithelium is modified and form the macula densa. The 
juxtaglomerular cells,macula densa,and the lacis cells are collectively known as 
juxtaglomerular apparatus. 
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The distal convoluted tubule length is 5mm. The distal tubule coalesce and form 
collecting duct that are 20 mm in length and traverse through the renal cortex and the  
medulla to empty into the renal pelvis at the apex of the medullary pyramids. the 
collecting duct epithelium contains principal cells(P cells) and intercalated cells(I cells) . 
The P cells are predominant cells in  regulation of Na+ reabsorption , vasopressin 
stimulated water reabsorption. 
The  I cells are very less in quantity, and  involved in acid secretion and HCO3-  transport.  
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CHRONIC KIDNEY DISEASE 
“Chronic kidney disease” is a spectrum of different pathophysiologic processes 
that are associated with abnormal kidney function and a progressive decline in glomerular 
filtration rate.  
 
KDOQI staging of CKD 
Stage     GFR, ml/min per 1.73m2  
0    >90 
1    > 90 
2    60-89 
3    30-59 
4    15-29 
5     <15 
 
Stage 0- comprises patients with risk factor for CKD.  
 
Stage 1 – comprises patients with demonstrated kidney damage. 
 
The term “Chronic renal failure” applies to the process of continuing significant 
irreversible reduction in number of nephrons and typically corresponds to CKD stages 3 
to 5.  
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The term “End stage renal disease” represents a stage of CKD, where the 
accumulation of toxins, fluid, electrolytes that are normally excreted by the kidneys 
resulting in  uremic syndrome..  
 
Risk Factors for CKD  
1) Hypertension  
2) Diabetes mellitus  
3) Autoimmune disease  
4) Older age  
5) Previous episode of acute kidney injury  
6) Proteinuria  
7) Abnormal urinary sediment 
8) Structural abnormality of urinary tract  
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Staging of CKD  
 
 For staging of CKD,it is necessary to estimate the GFR.  
 
 The two common formulas used to calculate e GFR are 
 
1. Cockcroft – Gault equation  
 Estimated creatinine clearance (ml/min)  
 
=  (140-age) x body weight (kg)  
72xPcr (mg/dL) 
 Multiply by 0.85 for women.  
 
2. Equation from the “ modification of Diet in Renal disease” study  
 
 Estimated GFR = 1.86 x [Pcr]-1.54 x (age) -0.203 
 Multiply by 0.742 for women  
 Multiply by 1.21 for African Americans. 
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FIGURE:6    GLOMERULAR ARCHITECTURE 
 
 
 Normal Glomerulus (1)       Hyperfiltering Glomerulus (2) 
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ETIOLOGY  
 
Leading categories of etiologies of CKD  
 
1) Diabetic glomerular disease  
2) Glomerulonephritis  
3) Hypertensive nephropathy  
4) Autosomal dominant polycystic kidney disease  
5) Other cystic and tubulo interstitial nephropathy  
 
 
Classification of CKD by Pathology  and etiology 
 
Pathology      etiology 
 
1) Diabetic glomerulosclerosis  Diabetes mellitus type 1 & 2  
 
2) Glomerular disase 
 Proliferative glomerulonephritis SLE, vasculitis,  
      Hepatitis B or C, HIV, Bacterial  
      Endocardititis 
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 Minimal change disease   Hodgkin diseases  
 Focal glomerular sclerosis  HIV, heroin toxicity  
     
 Membranous nephropathy     Drug toxicity, solid tumours 
 
 Fibrillary glomerular disease  Amyloidosis light chain disease  
 
 Hereditary nephritis   Alport’s syndrome  
 
3)Vascular disease 
  
 Disease of large size vessels   Renal artery stenosis, aorto arteritis 
 
 Disease of medium size   Hypertension  
 Vessels (nephrosclerosis)  
 
 Disease of small vessels   Haemolytic uremic syndrome 
 (microangiopathy)    Vasculitis, sickle cell disease  
 
 Tubulo interstitial disease  Infections, drugs, sarcoidosis 
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 Reflux nephropathy    Vesico – ureteric reflux 
 
 Obstructive nephropathy  Stones,prostatism, malignancy 
 
 Myeloma kidney   Multiple myeloma 
 
 
 
 
Cystic Disease 
 
 Polycystic kidney disease   Autosomal dominant 
 Tuberous sclerosis    or  
      Recessive 
 Von hippel – lindau disease  
 Medullary cystic disease 
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PATHOPHYSIOLOGY OF CHRONIC KIDNEY DISEASE  
 
Two broad sets of mechanisms of damage 
 (1) Initiating mechanisms specific to underlying etiology 
(2) A set of progressive mechanisms involving hyper filtration and hypertrophy of the 
remaining viable nephrons that are common consequence following long-term reduction 
in renal mass, irrespective of the underlying etiology. The responses to reduction in 
nephrons are mediated by vasoactive amines, cytokines and growth factors. 
Subsequently, the short term adaptations in the form of hyper filtration and hypertrophy 
becomes maladaptive with sclerosis and dropout of the remaining nephrons. Increased 
intrarenal activity of renin-angiotension axis contribute both the initial adaptive hyper 
filtration and to subsequent maladaptive hypertrophy and sclerosis. TGF – B stimulation 
also contribute to sclerosis of nephrons.  
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PATHOPHYSIOLOGY OF UREMIA  
 
 The pathophysiology of uremic syndrome divided into manifestation of three 
spheres of dysfunction.  
 
1) Those consequent to the accumulation of toxins and metabolites that are normally 
undergo renal excretion, including products of protein metabolism.  
 
2) Those consequent to loss of other renal functions, such as, fluid and electrolytes 
homeostasis and hormone regulation.  
 
3) Progressive systemic inflammation and its vascular and nutritional consequences.  
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CLINICAL AND LABORATORY MANIFESTATIONS OF CHRONIC KIDNEY 
DISEASE AND UREMIA 
 
 Uremia leads to disturbances in every organ system function.  
 
1) Fluid, electrolytes and acid – base disorders  
 a) Sodium and water homeostasis 
 
 In stable CKD patients, the total body content of sodium and water is modestly 
increased, this leads to extra cellular fluid volume (ECFV) expansion and contributes to 
hypertension.  
 
 Thiazide diuretics are limited utility in CKD stage 3 – 5, they need administration 
of loop diuretics. Ongoing diuretic resistance with intractable edema and hypertension in 
advanced CKD is an indication to initiate dialysis.  
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b)Potassium Homeostasis 
 
 Hyperkalemia is common in CKD due to increased dietary potassium intake, 
protein catabolism, haemorrhage, metabolic acidosis and due to medications like ACEI, 
ARBs and potassium sparing diuretics.  
 
 Diabetic kidney disease, obstructive uropathy, sickle cell uropathy associated with 
hyporeninemic hypoaldosteronism, cause more severe disruption of potassium secretory 
mechanisms in distal nephron causing  hyperkalemia.  
 
c) Metabolic acidosis: 
 
 It is a common abnormality in CKD. Most patients with CKD, produce less 
ammonia and hence, cannot excrete the normal quantity of protons in combination with 
urinary buffer. In addition, hyperkalemia depresses ammonia production. The 
combination of hyperkalemia and hyperchloremic metabolic acidosis is often present, and 
it a non-anion gap metabolic acidosis. With worsening renal function, the net urinary acid 
excretion is limited and retained anions of organic acids lead to anion gap metabolic 
acidosis. In most patients with CKD, the metabolic acidosis is mild, and usually be 
corrected with oral sodium bicarbonate supplementation.  
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2) Disorders of calcium and phosphate metabolism: 
 
 Manifested in skeleton and vascular bed  
 
a) Bone manifestations of CKD  
Classified into  
 
1)High bone turnover with increased PTH levels  
   [Including ostetitis fibrosa cystica]  
 2)Low bone turnover with low or normal PTH levels  
    (adynamic bone disease and ostemalacia)  
 
 
 
b)Cardiovascular system manifestations 
 
 Hyperphosphatemia is a major risk factor for increased cardiovascular mortality in 
patients with CKD.  
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 Hyperphosphatemia and hypercalcemia in CKD are associated with increased 
vascular calcification.  
 
 Calciphylaxis [calcific uremic arteriolopathy) is a dreaded complication seen 
almost exclusively in advanced CKD patients. It appears as livedo reticularis, and 
progress to necrotic lesions  in the legs, thigh, abdomen and breasts. It is seen in 
advanced hyperparathyroidism, increased use of oral calcium as a phosphate binder, and 
as a complication of warfarin therapy in haemodialysis patients.  
 
 Optimum management of secondary hyperparathyroidism and osteitis fibrosa is 
prevention. Current KDOQI guidelines recommends target PTH level between 150 and 
300pg/ml.  
 
 This can be achieved by  
- Low – phosphate diet  
- Phosphate binder [calcium acetate, calcium carbonate, lanthanum, 
sevelamer] 
- Calcitriol 
- Calci mimetic agents –cinacalcet 
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3) Cardiovascular abnormalities 
 
- Leading cause of morbidity and mortality in patients with any stage of 
CKD 
- The incremental risk of cardiovascular disease in CKD patients is 10 to 
200 fold when compared to age and sex matched general population. 
 
a) Ischemic vascular disease 
CKD augments the process of  
- Occlusive coronary disease 
- Cerebro vascular disease 
- Peripheral vascular disease 
 
Risk factors for cardiovascular disease in CKD  
Traditional     Non – Traditional (CKD related)  
Hypertension     Anemia  
Hypervolemia     Hyper phosphatemia 
Dyslipidemia     Hyperparathroidism 
Sympathetic over activity   Sleep apnea 
Hyper homocysteinemia   generalized inflammation  
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b)Heart failure  
c)Hypertension and left ventricular hypertrophy  
In all CKD patients, blood pressure should be controlled to levels 
recommended by national guideline panels.  
- Salt restriction should be the first line of therapy  
- Antiphypertensive agent choice is similar to that of general population.  
 
Lifestyle changes, including regular exercise should be advocated in the management of 
cardiovascular disease.  
 
Hyperlipidemia is managed with dietary measures and lipid – lowering medications such 
as statins. 
 
b) Pericardial disease 
 
Pericarditis, pericardial effusion is seen in advanced uremia. It is now more 
commonly observed in underdialyzed, non adherent patients than those in starting 
dialysis.  
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Uremic pericarditis is an absolute indication for emergency dialysis and for 
intensification of dialysis prescription.  
 
 
4) Hematologic abnormalities 
 
a) Anemia  
 
A normochromic, normocytic anemia is observed in stage 3 CKD, and is almost 
always by stage 4. 
 
Primary cause of anemia in CKD is insufficient production of erythropoietin 
(EPO)  
 
 The treatment of anemia in CKD patients are oral iron supplementation, IV iron 
infusion, vitamin B12 and folate, administration of recombinant human EPO and modified 
EPO products.  
b) Abnormal hemostasis  
Patients with advanced CKD have increased tendency to bleeding and bruising 
due to prolonged bleeding time, abnormal platelet aggregation and adhesion.  
 
Optimal dialysis restores hemostatic abnormalities.  
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5) Neuro muscular abnormalities 
 
 CNS, PNS, ANS, muscle structure and function abnormalities are well recognized 
complication of CKD.  
 
 Subtle clinical manifestations become evident at stage 3 CKD.  
 
 Early manifestations are memory disturbances, sleep disturbances.  
 
 Neuromuscular irritability such as hiccups, cramps, twitching occurs at later 
stages.  
 
 In advanced renal failure, asterixis, myoclonus, seizures and coma occurs.  
 
 Peripheral neuropathy usually evident of stage IV CKD. Most of the 
manifestations, described above resolved by dialysis.  
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6) Gastrointestinal and nutritional abnormalities 
           Uremic fetor.   
 Anorexia, nausea, vomiting.  
 Gastritis, peptic disease, mucosal ulceration.  
 Protein – energy malnutrition is common in advanced CKD.  
 Assessment of protein – energy malnutrition begin at stage 3 CKD.  
 
7) Endocrine – metabolic abnormalities  
 
- Glucose metabolism is impaired in CKD  
- Due to diminished renal degradation of insulin, the dose of insulin 
therapy need progressive reduction in dose.  
 
In women with CKD, estrogen levels are low, hence, menstrual irregularities and 
high rate of spontaneous abortion are common.  
 
In men, there is decreased plasma testosterone level and sexual dysfunction 
oligospermia may supervene.  
 
 
 
 
  
35 
  
8)Dermatologic abnormalities  
 
            Pruritus is very common.  
            Urochromes – due to deposition of retained pigmented metabolites.  
 
Nephrogenic fibrosing dermopathy – unique to CKD patients, consists of 
progressive subcutaneuous induration, especially on the arms and leg.  
 
Haemodialysis improve the cutaneous abnormalities but not the pruritus.  
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Approach to patients with CKD 
 
 1)History and physical examination.  
 
 Enquire about history of hypertension, diabetes mellitus, abnormal urinalysis and 
problems with pregnancy such as pre eclampsia or early pregnancy loss.  
 
 A careful drug history should be warranted. A careful family history of kidney 
disease should be elicited.  
 The physical examination should focus on blood pressure and target organ damage 
from hypertension. Thus fundoscopy and precordial examination should be carried out. 
Look for edema and sensory polyneuropathy.  
 
 2)Laboratory examination  
 
 Lab studies should focus to find the clues of the underlying causative or 
aggravating disease process.  
 
 Serial measurements of renal function should be done to determine the pace of 
renal deterioation, serum concentration of calcium, phosphorus, vitamin D, PTH, 
haemoglobin level, iron, B12, folate level and 24-h – urine protein excretion all should be 
measured.  
  
37 
  
 
 Imaging studies 
 Renal ultrasound is the most useful imaging study. It verifies the presence of two 
kidneys, determine their symmetricity, allow an estimation of kidney size.  
 
 . Doppler sonography, nuclear medicine studies, CT or MRI to diagnose 
renovascular disease. A voiding cystogram to rule out reflux nephropathy.  
 
 Treatment of CKD  
 Treatment strategy aimed at specific causes of CKD. These include strict glucose 
control in DM and immunomodulatory agents for glomerulonephritis. It is useful to 
sequentially measure and plot the rate of decline of GFR in all patients.  
 
 A thorough search for aggravating factor is warranted to reverse the acute or 
subacute process in the setting of CKD.  
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Clinical action plan 
 
stage description GFR, ml/min 
per 1.73m2 
Action 
1. Kidney damage with 
normal or ↑ GFR 
≥90 Diagnosis and treatment of 
comorbid conditions, slowing of 
progression of CVD risk reduction. 
2. Kidney damage with  
mild ↓ GFR  
60-89 Estimating progression. 
3. Moderate ↓GFR 30-59 Evaluating and treating 
complications 
4. Severe ↓ GFR  15-29 Preparation for kidney replacement 
therapy. 
5. Kidney failure ≤15 Kidney replacement. 
 
Slowing the progression of CKD  
 Reducing intra glomerular hypertension and proteinuria 
 Control of blood glucose  
 Control of blood pressure and proteinuria  
 Protein restriction  
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Indication for dialysis 
 
 Fluid overload or pulmonary edema refractory to diuretics. 
 
Uremia: Pericarditis, persistent nausea, vomiting, bleeding due to platelet 
dysfunction, progressive uremic encephalopathy.  
 
 Refractory hyperkalemia  
 Metabolic acidosis 
 Serum creatine above 10mg/dl 
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Renal replacement therapies 
The renal replacement therapies are chronic maintenanance haemodialysis, chronic 
peritoneal dialysis and kidney transplantation. Kidney transplantation is the treatment of 
choice in end stage renal disease(ESRD). 
Dialysis 
The term “dialysis” was coined by Thomas graham, professor of chemistry  at Anderson 
university in Glasgow  in 1861. The first successful human dialysis was performed by 
George  hass from germany  in 1924. In 1943 the first practical human haemodialysis 
machine  was developed by kolf  and berk from Netherlands. This first machine was 
rotating  drum articifial kidney consisted of 30 to 40 meters of cellophone tubing in a 
stationary 100 litres tank. 
Use of dialysis was restricted to acute renal failure from 1943 to 1960( ARF).  The 
discovery of arteriovenous shunt by Quinton  and scribner in 1960 and forearm 
arteriovenous fistula by Brescia and cimino in 1966 extended this modality of therapy to 
chronic end stage renal failure. 
Chronic maintenance haemodialysis, now emerged as one of well established life 
sustaining therapy in terminally ill end stage renal failure patients. 
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In India, the first successful haemodialysis was started by Christian medical college, 
vellore, Tamilnadu. 
Selection of dialysis  
Selecting one of the dialysis modalities is influenced by many factors, such as 
availability,convenience, comorbid conditions, socio-economic, and haemodynamic 
stability. Most CKD patients can be treated with either peritoneal dialysis (PD) or 
haemodialysis (HD). Continuous ambulatory peritoneal dialysis (CAPD) is the preferred 
dialysis modality in young children, elderly patients in whom vascular access is not 
available and in haemodynamically unstable patients. In a single patient all modalities of 
dialysis can be utilized. In the beginning start with PD when residual kidney function is 
present and later on switch over to HD when the patient becomes anuric. 
Principles of dialysis 
Diffusion  
If different concentrations of two solutions are separated by a semipermeable membrane, 
solution from the side of high concentration will move to lower solute concentration side. 
This solute movement process on a concentration gradient is known as diffusion.            
The diffusion rate is highest when the concentration is high. This is the principle 
mechanism for clearance of urea, creatinine and for replenishment of serum bicarbonate. 
Other determining factors of diffusion are solution temperature, viscosity, molecule size, 
and membrane characteristics. 
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Ultrafiltration 
This is a convective transport. Due to the extremely smaller molecular size, water can 
pass through all semipermeable membrane and ultrafiltration occurs when water driven 
by either an osmotic or a hydrostatic force pushed through the membrane. The solutes 
that can pass easily through the membrane pores are swept along with the water and this 
process is known as “solvent drag”. This principle is mainly used for removal of water 
from body. 
Clinically, both diffusion and ultrafiltration movement take in and out of blood, across a 
semipermeable membrane. If the blood is exposed to an artificial membrane outside the 
body, i.e. extracorporeal circulation, the process is known as haemodialysis or 
haemofiltration. If the exchange of molecules takes place across the peritoneal 
membrane,the process is known as peritoneal dialysis(PD). 
 Haemodialysis  
Components of  haemodialysis. 
1)Blood circuit. 
2)Dialysis fluid circuit. 
3)Dialyzer. 
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Vascular access 
It is the lifeline for the patient and Achilles heel of HD. The vascular access help to draw 
blood continuously from the patient at a required rate of between 200 to 400 ml per 
minute and return to the patient after circulating it through the artificial kidney. 
Temporary vascular access 
This is for patients requiring shorter period of HD, such as those with AKI, and patients 
waiting for permanent access requires urgent dialysis. 
Preferred  vascular access sites. 
1)Right internal jugular vein 
2)Femoral vein 
3)Left internal jugular vein 
4)Right subclavian vein. 
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Permanent vascular access 
Native arteriovenous fistula (AVF) ,non-dominant radio-cephalic is the vascular access of 
choice for long-term maintenance haemodialysis. AVF has longest life with least 
complications, so arm veins should be preserved in all patients likely to require dialysis.  
 
AVF should be construted when GFR falls below 25ml/min ,AVF takes 3 – 4 months for 
its full development and it should not be used at least one month after its creation. 
Frequency of dialysis 
A four hours dialysis of three cycles per week is desirable. Dialysis frequency should be 
increased for patients with cardiovascular problems. 
Complications of hemodialysis 
 
Acute vascular access/ fistula related 
 
Haemorrhage, haemothorax, 
pneumothorax. 
Chronic AVF related Infection, aneurysm, steal, venous 
congestion, high output failure. 
Extra corporeal circulation procedure 
related 
Dialyser reactions, type A anaphylactic 
reactions, hypotension, hypoxia, cramps, 
fever, chills, dialysis disequilibrium, air 
embolism. 
Chronic complications Hepatitis B and C infections, metabolic 
bone disease, worsening of 
anaemia,dialysis dementia. 
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Peritoneal dialysis  
The physiological basis  of this technique across the peritoneum entails the process of 
diffusion, connective transport and osmosis. In PD, solute and fluid exchange occurs 
between the peritoneal capillaries and the dialysis solution in the peritoneal cavity. 
Components of PD 
1) PD catheter 
2) PD solution 
3) Peritoneal membrane with its associated vasculature. 
Peritoneal dialysis modalities 
1) Continuous ambulatory peritoneal dialysis 
2) Continuous cycling peritoneal dialysis 
3) Nocturnal intermittent peritoneal dialysis 
4) Tidal peritoneal dialysis. 
Complications of peritoneal dialysis 
Technical complications : catheter related exit site infection, tunnel infection, peritonitis. 
Raised intra-abdominal pressure: hernias, fluid leak, prolapsed rectum,vagina 
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Renal transplantation  
The first successful renal transplantation done in 1956 in USA. In India , in 1971 first 
successful renal transplantation done in Christian medical college, vellore. Currently 
about 3500 renal transplants are done annually in India.  
Transplantation immunology 
There are three phases of immune response to a transplanted allograft. 
1) Recognition of foreign antigens. 
2) Activation of antigen specific lymphocytes. 
3) Effector phase of graft rejection 
 
Drugs for immunosuppresion 
Currently in india, most patients receiving a triple drug regimen including 
tacrolimus,mycophenolate mofetil, and prednisolone for the maintenance of 
immunosuppression. 
Transplantation procedure 
The donar nephrectomy can be done laparoscopically and this reduces the morbidity 
and the hospital stay. The recipient has the allograft implanted in the iliac fossa with 
the anastomosis of the donar vessels to the iliac vessels and the ureter implanted into 
the recipient bladder using antireflux technique. 
  
47 
  
 
 
Post-transplant complications 
1) Infections.  
2) Rejection. 
3) Vascular disorders. 
4) Recurrence of glomeruler disorders. 
 
Survival after transplantation. 
Survival after transplantation in india  at 1,5 and 10 years is about 97%, 80&, 60% 
respectively. 
 
 
Immunosuppressive therapy 
A combination  of drugs are used to prevent graft  rejection.The commonly used drugs 
are steroids, calcineurin inhibitors (cyclosporine, tacrolimus), azathioprine, 
mycophenolate mofetil. 
Complications: Hyperacute rejection, acute rejection, chronic rejection, infection. 
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Vitamin D and CKD 
 
 CKD is a public health problem and a powerful predictor of premature 
cardiovascular  complications may be linked to vitamin D deficiency. CKD patients have 
a high rate of severe hypovitaminosis D.  
 
 Vitamin D plays a vital role as a cell differentiating and anti-proliferative factor 
with actions in a wide variety of tissues. In CKD patients the new non classical role of 
Vitamin D also encompasses regulation of renin angiotensin system  and the nuclear 
factor (NF) kB pathway, both are implicated in wide variety of chronic disease.  
 
 Numerous evidences conclude adequate replacement of Vitamin D potentially 
reduce premature morbidity and mortality in CKD patients.  
 
Non classical role of vitamin D: 
  
 Research evidences highlights a peripheral autocrine pathway, for production of 
calcitriol in non-renal tissues. Calcitriol synthesized in this peripheral tissues mediates the 
reactions  that bridge the external stimuli to gene transcription.  
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 This non classical pathway discovery ignites new significance to the importance of 
addressing nutritional Vitamin D deficiency given the potential role that hypovitaminosis 
D may play in multiple chronic disease Vitamin D deficiency is  in greater degree in 
patients with CKD.  
 
Non  classical role of Vitamin D in CKD 
 
 Kidneys appear to be a major target organ for both classical and non classical 
functions of Vitamin D, due to highly expression of Vitamin D receptors in the kidneys.  
 
The specific pathway that is regulated by the autocrine function of Vitamin D in the CKD 
patients is the renin- angiotensin system . 
 
 The resulting sequence activates angiotensin ІІ, in CKD patients, have harmful 
effects on blood pressure and  vascular tissue, and  lead to renal parenchymal damage.. 
These deleterious effects are reversed through modulation of RAS system, by the effects 
on blood pressure and on the dysregulated vascular and cardiac function.  
  
 In experimental models of different stages of CKD, administration of activated 
vitamin D analogs, results in suppressed activation of  RAS system along with concurrent 
reduction of glomerular and tubulointerstitial destruction leads to improvement in blood 
pressure.  
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 Another significant role of RAS is in diabetic nephropathy, a leading cause of 
CKD.  
 
 Hyperglycaemia and vitamin D deficiency both are strong stimulators of the intra  
renal component of the RAS. In experimental diabetic models vitamin D analogues 
supplementation have a therapeutic advantage by potentiating the traditional inhibitors of 
RAS.  
 
 Albuminuria is one of the classical sign of nephropathy. Research evidences  
demonstrate the negative relationship between the level of Vitamin D and degree of 
Albuminuria. These findings suggested that vitamin D also have anti proteinuric effect 
likely via RAS  mediated mechanism.  
 
 Besides its roles in progression of kidney disease and proteinuria, the locally 
synthesized intrarenal angiotensin II has a harmful outcome on the cardiovascular system 
by its effect on blood pressure, vascular smooth muscle cells and cardiac myocytes. Since 
cardiovascular disease is the predominant cause of death in CKD patients the potential 
role of Vitamin D supplementation to positively regulate this RAS system may be quiet 
significant in affecting the premature death associated with CKD.  
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NF – kB pathway 
 
 Another important pathway in CKD, which may be regulated by the non  classical 
autocrine actions of vitamin D is the NF – kB pathway. NF – kB refers to a group of 
transcription factors which modulate the genes involved in the immune responses, 
inflammatory processes and fibrosis, the factors  implicated in the pathogenesis of CKD. 
Stimulation  of NF – kB pathway activates a series of events results in production of 
cytokines, chemokines ,many other inflammatory factors, which exacerbates tissue injury 
in the renal disease process.  
 
   
 
 
Treatment 
 Due to progression of CKD, the renal mass decreases, as well as the capacity of  
renal hydroxylation of 1, 25 vitamin D diminishes and 1, 25 vitamin D deficiency occurs. 
Therefore  repletion of 1, 25 Vitamin D either by using calcitriol or its analogues is 
mandatory to overcome the compromised production of 1,25 vitamin D, so that the 
classical functions of 1, 25 vitamin D to be established.  
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 All patients with CKD are considered to have sub optimal level of Vitamin D 
when serum values less than 30-32ng /ml and several recent reports suggest that optimal 
serum level of 25(OH) vitamin D should be between 40 to 80ng/ml.  
 
 Since Vitamin D does not naturally occurs in most foods the use of vitamin D 
supplements is now almost universally required.  
 
 Supplementation can be safely achived with the use of vitamin D3 or D2 in the 
oral formulation.  
 
 Vitamin D3 (or) cholcalciferol, the natural form of the vitamin D, is the superior 
form and have some advantage over vitamin D2 (ergocalciferol) by increased potency and 
decreased rate of metabolic degradation.  
 
 In CKD patients supplementation of 25(OH) vitamin D is recommended at the 
inception of the disease with the addition of calcitriol in stage 3.  
 
 Newer studies suggest that doses as high as 4000 IU daily may be required to 
maintain optimum vitamin D levels in normal population and it is extrapolated that 
higher doses may be required in CKD patients to overcome the more profound deficits to 
which they are prone. To achieve adequate repletion one common estimation is that each 
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100 IU of vitamin D administration will raise the serum 25(OH) vitamin D level by 
1ng/ml.  
 
Conclusion  
  
 Vitamin D has established as a vital compound in the management of CKD with 
newly ascribed autocrine functions vastly different from its classical function over 
mineral homeostasis. To ignore vitamin D importance, and its potential impact on 
mortality and morbidity in CKD patients are no longer appropriate. In addition to the 
traditional supplementation of 1, 25 vitamin D to CKD patients, by assessing vitamin D 
deficiency and eliminating the deficiency with vitamin D, the physicians will adequately 
fuel both the renal and extra renal pathways of calcitriol synthesis maintaining the 
classical and non classical functions of vitamin D that ultimately influence the clinical 
outcome in CKD patients.  
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AIMS AND OBJECTIVE 
 
 To evaluate the vitamin D deficiency in chronic kidney disease patients in relation 
to gender, diabetes mellitus, systemic hypertension. 
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 MATERIALS AND METHODS  
 
SETTING    : INPATIENTS  
     OUTPATIENTS 
HOSPITAL    : THANJAVUR MEDICAL COLLEGE HOSPITAL 
     THANJAVUR. 
 
ETHICAL COMMITTEE APPROVAL :  YES OBTAINED  
 
DESIGN OF STUDY   : OBSERVATIONAL AND PROSPECTIVE  
      SINGLE CENTERED STUDY  
 
PERIOD OF STUDY   : 2013 SEPTEMBER TO 2015 JUNE 
 
SAMPLE SIZE    : 60 PATIENTS  
 
 
 
 
 
 
  
56 
  
SELECTION OF PATIENTS  
 
 
INCLUSION CRITERIA  
 
PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 2 – 4  
 
EXCLUSION CRITERIA  
 
1. CKD PATIENTS ON DIALYSIS THERAPY  
2. CKD PATIENTS ON VITAMIN D SUPPLEMENTATION. 
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STUDY METHODOLOGY 
 
 60 patients with chronic kidney disease were selected for the study. Patients on 
dialysis and on Vitamin D therapy were excluded from the study.  
 
 15 female patients, 15 male patients with CKD with diabetes mellitus, 15 male 
patients with hypertension, 15 male patients without diabetes mellitus  and hypertension 
were selected for the study.  
 
 Diagnosis of CKD over based on history, clinical features, USG abdomen and 
renal function test and eGFR 
 
 The following investigations were done on admission: 
1. Complete blood count  
2. Random blood sugar  
3. Serum urea and creatinine 
4. Serum vitamin D level  
5. Serum electrolytes  
6. USG abdomen  
7. Fasting and post prandial blood sugar  
8. ECG 
9. Urine analysis  
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MEASUREMENT OF VITAMIN D 
For assessing vitamin  D status the best indicator is circulating 25 hydroxyl vitaminD (25 
OH D) .  
Currently used 2 main methods are  
1.competitive immune assay 
2.chromatographic separation followed by non- immunological direct detection[HPLC, 
LC-MS/MS]. 
Our study based on fully automated chemi luminescent immuno assay (LC-MS/MS) 
which employs non-immunological direct detection.  
The currently used LC-MS/MS method used automated platform. 
According to this method vitamin D status measured as  
 Deficiency       : <20 ng/ml 
 Insufficiency   : 20-30ng/ml 
 Sufficiency      : 30-100 ng/ml 
 Toxicity           : >100ng/ml 
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OBSERVATION AND RESULTS 
60 Chronic kidney disease patients were included in the study.  Serum vitamin D 
level was measured and results were analysed. 
Among the 60 chronic kidney disease patients 15 were Female and 45 were male. 
Patients selected for study. 
TABLE -1 : SEX DISTRIBUTION IN THE STUDY 
SEX NUMBER OF PATIENTS PERCENTAGE 
MALE 45 75% 
FEMALE 15 25% 
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FIGURE 7 : SEX DISTRIBUTION IN THE STUDY 
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STAGE OF CKD 
This study includes CKD patients with stage 2-4. 
Out of 60 patients 
9 were in stage 3. 
51 were in stage 4. 
TABLE – 2 : STAGE DISTRIBUTION OF CKD PATIENTS 
STAGE NUMBER OF PATIENTS PERCENTAGE 
Stage 2 0 0 
Stage 3 9 15% 
Stage 4 51 85% 
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FIGURE:8 
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Among 9 patients with stage 3 CKD  
2 were Female patients 
7 were male patients. 
Among 51 patients with stage 4 CKD 
13 were Female patients. 
38 were male patients . 
FIGURE:9 
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Among the 15 Female patients 
3 had Diabetes mellitus as a risk Factor 
4 had Hypertension as a risk Factor remaining 8 patients had no risk Factors. 
Among the 45 male patients 
15 had Diabetes mellitus as a risk Factor. 
15 had Hypertension as a risk Factor 
15 patients were without any risk Factors. 
 
TABLE  3: RISK FACTORS IN MALE AND FEMALE CKD PATIENTS 
RISK FACTORS MALE-CKD FEMALE-CKD 
DIABETES MELLITUS 15 3 
HYPERTENSION 15 4 
NO RISK FACTORS 15 8 
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FIGURE 10 :SHOWING RISK FACTORS DISTRIBUTION  AMONG MALE & 
FEMALE CKD PATIENTS. 
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CKD PATIENTS WITH VITAMIN D DEFICIENCY 
Of the 60 patients included in the study 52 patients had vitamin D deficiency and 
only 8 patients had sufficient vitamin D Level. 
 Hence the study shows an increased prevalence of vitamin D deficiency in CKD 
patients. 
TABLE 4:   CKD PATIENTS WITH VITAMIN D DEFICIENCY 
SERUM VITAMIN 
D LEVEL 
NUMBER OF PATIENTS PERCENTAGE 
NORMAL 8 13% 
DEFICIENCY 52 87% 
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FIGURE:11 
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GENDER ANALYSIS OF VITAMIN D DEFICIENCY 
Among the 15 female CKD patients 14 patients had vitamin D deficiency. 
Among the 45 male CKD patients 38 patients had vitamin D deficiency. 
TABLE 5:   GENDER ANALYSIS OF VITAMIN D DEFICIENCY 
SEX TOTAL NO OF 
PATIENTS 
PATIENTS WITH 
VITAMIN D 
DEFICIECY 
PERCENTAGE 
Female 15 14 93% 
Male 45 38 84% 
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FIGURE12: 
 
 
 
 
This analysis shows Female CKD patients have higher vitamin D deficiency 
prevalence than male CKD patients. 
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ANALYSIS  OF VITAMIN D DEFICIENCY IN MALE CKD PATIENTS 
WITH  HYPERTENSION AND DIABETES MELLITUS. 
Out of 15 male patients with Hypertension 13 patients had vitamin D deficiency. 
Out of 15 male patients with Diabetes mellitus all patients had vitamin D 
deficiency. 
 
TABLE 6:    RISK FACTOR ANALYSIS OF VITAMIN D DEFICIENCY IN 
MALE CKD PATIENTS 
RISK 
FACTOR 
TOTAL PATIENTS  PATIENTS WITH 
VITAMIN D 
DEFICIECY 
PERCENTAGE 
Hypertension 15 13 87% 
Diabetes 
mellitus 
15 15 100% 
 
This table shows CKD patients with diabetes mellitus as a risk Factor almost 
always have vitamin D deficiency as compared to hypertension.  
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  TABLE 7 :AVERAGE VITAMIN D LEVEL BETWEEN TWO GROUPS 
VITAMIN D AVERAGE VITAMIN D 
DEFICIENCY GROUP 17.23 
SUFFICIENT GROUP 35.37 
 
FIGURE:13 
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Statistical analysis 
item  n Min. Max. Mean  S.D 
Age 60 22 75 48.05 10.998 
Vitamin d level 60 7.96 42.40 19.8083 8.13228 
 
Age  
Particulars 
frequency 
(n=60) 
percentage 
(100%) 
Below 30yrs 3 5.0% 
31 to 40yrs 15 25.0% 
41 to 50yrs 17 28.3% 
51 to 60yrs 19 31.7% 
61 to 70yrs 5 8.3% 
71yrs & above 1 1.7% 
Sex 
Particulars 
frequency 
(n=60) 
percentage 
(100%) 
Male 45 75.0% 
Female 15 25.0% 
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Vitamin d level 
Particulars 
frequency 
(n=60) 
percentage 
(100%) 
Deficiency (Below 20ng ml) 51 85.0% 
Sufficiency (30 to 100 ngml) 9 15.0% 
 
Chi-square test  
Age 
Female CKD 
patients 
Male CKD 
patients 
without any 
risk factors 
Male CKD 
patients with 
hypertension 
Male CKD 
patients with 
diabetes 
Total Statistical 
inference 
(n=15) (100%) (n=15) (100%) (n=15) (100%) (n=15) (100%) (n=60) (100%) 
Below 
30yrs 
1 6.7% 0 .0% 1 6.7% 1 6.7% 3 5.0% 
X2=7.872 
Df=15 
.929>0.05 
Not 
Significant  
31 to 
40yrs 
3 20.0% 5 33.3% 4 26.7% 3 20.0% 15 25.0% 
41 to 
50yrs 
4 26.7% 6 40.0% 4 26.7% 3 20.0% 17 28.3% 
51 to 
60yrs 
6 40.0% 3 20.0% 4 26.7% 6 40.0% 19 31.7% 
61 to 
70yrs 
1 6.7% 1 6.7% 1 6.7% 2 13.3% 5 8.3% 
71yrs 
& 
above 
0 .0% 0 .0% 1 6.7% 0 .0% 1 1.7% 
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Chi-square test 
Sex 
Female CKD 
patients 
Male CKD 
patients 
without any 
risk factors 
Male CKD 
patients with 
hypertension 
Male CKD 
patients with 
diabetes 
Total Statistical 
inference 
(n=15) (100%) (n=15) (100%) (n=15) (100%) (n=15) (100%) (n=60) (100%) 
Male 0 .0% 15 100.0% 15 100.0% 15 100.0% 45 75.0% X2=60.000 
Df=3 
.002<0.05 
Significant 
Female 15 100.0% 0 .0% 0 .0% 0 .0% 15 25.0% 
 
Chi-square test 
Vitamin d level 
Female CKD 
patients 
Male CKD 
patients without 
any risk factors 
Male CKD 
patients with 
hypertension 
Male CKD 
patients with 
diabetes 
Total 
Statistical 
inference 
(n=15) (100%) (n=15) (100%) (n=15) (100%) (n=15) (100%) (n=60) (100%) 
Deficiency 
(Below 20ng 
ml) 
9 60.0% 8 53.3% 11 73.3% 11 73.3% 39 65.0% X2=7.470 
Df=6 
.280>0.05 
Not 
Significant 
Insufficiency 
(20 to 30ng ml) 
5 33.3% 2 13.3% 2 13.3% 3 20.0% 12 20.0% 
Sufficiency (30 
to 100 ngml) 
1 6.7% 5 33.3% 2 13.3% 1 6.7% 9 15.0% 
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Oneway ANOVA  
 
Vitamin D 
level 
n Mean  S.D SS Df MS Statistical 
inference  
Between 
Groups 
   
385.216 5 77.043 
f=1.183 
0.004<0.05 
 Significant  
Below 30yrs 3 14.7033 5.06488    
31 to 40yrs 15 21.3240 10.10091    
41 to 50yrs 17 21.5653 8.99189    
51 to 60yrs 19 19.6432 6.18197    
61 to 70yrs 5 13.2000 3.72210    
71yrs & above 1 18.7000 0.00000    
Within Groups    3516.687 54 65.124 
 
T-Test 
Vitamin d level n Mean  S.D t df Statistical inference  
Male 45 19.7311 8.62121 
-.126 58 
0.04<0.05 
 Significant Female 15 20.0400 6.71095 
 
T-Test 
Age n Mean  S.D t df Statistical inference  
Male 45 48.04 10.954 
-.007 58 
.995>0.05 
Not Significant Female 15 48.07 11.517 
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Oneway ANOVA  
Vitamin d level n Mean S.D SS Df MS 
Statistical 
inference 
Between Groups    204.078 3 68.026 
0.03<0.05 
 Significant 
Female CKD patients 15 20.0400 6.71095    
Male CKD patients 
without any risk 
factors 
15 22.2773 9.09594    
Male CKD patients 
with hypertension 
15 19.8380 9.41512    
Male CKD patients 
with diabetes 
15 17.0780 6.90746    
Within Groups    3697.825 56 66.033 
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Oneway ANOVA 
Age n Mean S.D SS Df MS 
Statistical 
inference 
Between Groups    33.917 3 11.306 
f=.089 
.966>0.05 
Not 
Significant 
Female CKD patients 15 48.07 11.517    
Male CKD patients 
without any risk factors 
15 46.87 8.442    
Male CKD patients with 
hypertension 
15 48.33 12.099    
Male CKD patients with 
diabetes 
15 48.93 12.533    
Within Groups    7102.933 56 126.838 
 
 
Statistical analysis of our study is significant of vitamin D deficiency in relation to female 
CKD patients, male CKD patients with diabetes mellitus, male CKD patients with 
hypertension,male CKD patients without diabetes and hypertension. 
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DISCUSSION 
CKD is now emerged as a global epidemic. It is a strong predictor of premature 
cardiovascular disease. Numerous studies suggest progression of CKD and its 
complications particularly cardiovascular complications are related to hypovitaminosis D. 
Many studies show patients with CKD have a higher degree of vitamin D 
deficiency status. 
A study by A. Lenin, GL Bakris, M. Molitch and D.L. Andress conclude 
vitamin D deficiency was evident at all stages of CKD. In their study 13% have vitamin 
D deficiency with eGFR > 80ml/min and >60%  in those with eGFR <30ml/min.  
Our study shows 36% of patients with stage 3 CKD that is those with eGFR > 
30min/min and 92% of stage 4 CKD patients, those with eGFR  <30/min had vitamin D 
deficiency. Our study was consistent with the study of A. Lein et al. 
In an another study conducted by Gonzalez E.A., Sachdeva.A. Oliver D.A and 
Martin K.J., Conclude 86% of Predialysis patients i.e., patients with stage 3 and stage 4 
CKD, had vitamin D deficiency. Their study also conclude 97% of the patients who were 
undergoing maintenance hemodialysis had vitamin D deficiency. Our study showed 87% 
of patients with stage 3 and 4 (Pre dialysis patients) had vitamin D deficiency, and 
consistent with the study of Gonzalez et al. 
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Another multivariate study conducted by Mohd rozita, A. Gafor halim, Chiew 
tong showed higher prevalence of vitamin D deficiency in Female patients with CKD. 
A study conducted by Del valle, Negri AL, Aguirre C, found that mean 25 (OH) 
D Levels were significantly higher in men that in women (28.6 ng/ml vs 18.9 ng/ml). 
Our study showed 93% of Female CKD patients have vitamin D deficiency as 
compared to 84% of male CKD patients with vitamin D deficiency. Hence our study is 
consistant with study by Mohd rozita et.al. 
In our study the mean 25 (OH) D Levels are almost similar in both men and 
women (male 19.5 ng/ml us Female 20.04. ng/ml) and contradict with the study by Del 
valle et al. 
A randomized trial of VDRA – vitamin D receptor activity in patients with CKD 
by Dr. Rajiv agarwal, Found that all patients (40 patients) in their study had vitamin D 
deficiency. Their study also demonstrate patients with proteinuria had higher proportion 
of vitamin D deficiency our study also witnessed that patients with proteinuria had higher 
proportion of vitamin D deficiency and consistent with the study of Rajiv agarwal et al. 
Another study regarding vitamin D and cardiovascular disease risk by michos, 
Erin D, Found 78% of hypertensive patients had vitamin D level in sub optimal range. 
They also found that 92% Diabetic patients had vitamin D deficiency. Our study showed 
almost all patients with Diabetes had vitamin D deficiency and 87% of hypertensive 
patients had sub optimal vitamin D level.  
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CONCLUSION 
1. Our study shows vitamin D deficiency in majority of CKD patients around 87%. 
2. Our study shows that female preponderance of vitamin D deficiency as compared 
to male CKD patients. 
3. Our study also shows CKD patients with Diabetes mellitus almost always have 
vitamin D Deficiency as compared to patients with Hypertension. 
4. Since vitamin D deficiency is associated with all stages of CKD, vitamin D has 
established as an important compound in the management of CKD. In CKD 
supplementation of 25 (OH) vitamin D is recommended at the inception of the 
disease and the addition of calcitriol in stage 3.  
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CONSENT FORM 
 
I 
here by give consent to participate in the study conducted by postgraduate in Department 
of General Medicine, Thanjavur Medical College, Thanjavur Medical College& Hospital, 
Thanjavur.,and to use my personal clinical data and result of investigation for the purpose 
of analysis and to study the nature of disease. I also give consent for further 
investigations. 
 
Place : 
Date : 
                                                                                              Signature of the participant 
     PROFORMA 
 
AN ANALYTICAL STUDY OF VITAMIN D DEFICIENCY IN CHRONIC  
 
KIDNEY DISEASE PATIENTS. 
 
NAME :          IP NO : 
           OP NO : 
 
AGE     :     DOA :    DOD   : 
PRESENTING ILLNESS : 
 
PAST HISTORY : 
DIABETES MELLITUS : 
HYPERTENSION           : 
RECURRENT UTI          : 
STD                                  : 
CHRONIC NSAIDs INGESTION : 
 
PERSONAL HISTORY 
SMOKING          : 
ALCOHOLISM  : 
 
FAMILY HISTORY : 
 
CLINICAL EXAMINATION : 
GENERAL EXAMINATION : 
BP :      PR: 
CVS: 
RS: 
P/A: 
CNS: 
 
 
 
 
INVESTIGATIONS   
CBC : 
HB : 
TC : 
RED CELL COUNT : 
PLATELET COUNT : 
PCV : 
RANDOM BLOOD SUGAR : 
FASTING BLOOD SUGAR : 
POST PRANDIAL BLOOD SUGAR : 
SERUM UREA : 
SERUM CREATININE : 
SERUM Na+ : 
SERUM K+  
 
 
 
URINE ANALYSIS: 
SERUM VITAMIN D LEVEL : 
USG ABDOMEN : 
ECG :                              
      
 S. 
No 
NAME AGE SEX DIABETES HYPERTENSION RBS FBS PPBS UREA CREATININE 
1. Dhanalakshmi 50 F No Yes 113mg 82 141 50mg 2.4 
2. Thamaraiselvi 41 F Yes Yes 188 169 214 160 5.2 
3. Vembayee 36 F No No 119 78 138 136 4.4 
4. Sigappayee 56 F Yes - 273 188 248 142 3.2 
5. Vijaya 47 F No Yes 94 76 112 110 3.4 
6. Parvathi 60 F No No 132 88 136 131 2.8 
7. Nallambal 58 F No No 68 78 124 88 2.2 
8. Poongodi 33 F Yes Yes 310 142 234 8 3.1 
9. Prema 52 F No Yes 92 110 132 96 3.5 
10. Azhagammal 50 F No No 72 81 108 110 4.5 
 
 
  
 S. 
No 
NAME AGE SEX DIABETES HYPERTENSION RBS FBS PPBS UREA CREATININE 
11. Anjammal 67 F No No 85 84 112 108 3.5 
12. Manimegalai 34 F No No 117 92 138 167 5.0 
13. Padma  32 F No No 81 92 130 142 5 
14. Russiya 55 F No No 96 84 126 88 2.0 
15. Malliga 56 F No Yes 105 88 130 90 1.8 
16. Kumarasamy 50 M No No 106 88 124 68 3.6 
17. Azhagar 48 M No No 123 82 112 70 3.0 
18. Tamilarasu 40 M No No 81 86 121 114 6.0 
19. Murugesan 40 M No No 116 92 136 164 6.5 
20. Shanmugam 40 M No No 82 104 138 128 7.0 
 
  
 S. 
No 
NAME AGE SEX DIABETES HYPERTENSION RBS FBS PPBS UREA CREATININE 
21. Thangadurai 42 M No No 74 78 112 102 4.8 
22. Srinivasan 54 M No No 68 76 124 148 6.0 
23 Kennedy 35 M No No 106 88 136 114 5.1 
24 Krishnamoorthi 37 M No No 96 76 126 184 8.0 
25. Singarayar 62 M No No 117 96 140 154 5.1 
26. Rajendran 47 M No No 87 91 126 130 6 
27. Elangovan 47 M No No 136 86 134 89 2.4 
28. Pakkirisamy 57 M No No 74 70 130 142 5.6 
29. Settu 50 M No No 93 82 136 166 6.2 
30. Manikandan 37 M No No 92 104 138 112 3.1 
 
  
 S. 
No 
NAME AGE SEX DIABETES HYPERTENSION RBS FBS PPBS UREA CREATININE 
31. Sundarrajan 57 M No Yes 124 102 142 146 5.4 
32. Punniyamoorthi 41 M No Yes 89 96 130 46 2.8 
33. Madhiyazhagan 55 M No Yes 127 102 136 132 4.9 
34. Kamaldeen 47 M No Yes 84 90 138 152 5.7 
35. Yesupillai 40 M No Yes 83 92 140 166 7 
36. Arumugam 62 M No Yes 74 84 130 142 5.1 
37. Arivazhagan 40 M No Yes 93 88 132 168 7.3 
38. Jothi 60 M No Yes 80 102 138 142 4.7 
39. Vijay 41 M No Yes 99 105 138 161 4.7 
40. Ramalingam 30 M No Yes 120 102 138 146 4.5 
 
  
 S. 
No 
NAME AGE SEX DIABETES HYPERTENSION RBS FBS PPBS UREA CREATININE 
41. Govintharaj 75 M No Yes 86 76 126 102 2.8 
42. Ramachandran 56 M No Yes 98 102 134 138 5.4 
43. Ragamathullah 35 M No Yes 85 105 138 92 3.0 
44. Sowrinayagam 40 M No Yes 98 78 136 130 5.1 
45 Jayakumar 46 M No No 102 86 140 142 5.7 
46 Kumaresan 53 M Yes No 188 164 210 84 4.0 
47. Ramesh 38 M Yes No 280 194 314 102 3.8 
48. Perumal 55 M Yes No 266 210 326 132 4.8 
49. Annadurai 45 M Yes No 212 169 246 109 3.5 
50. Saminathan 48 M Yes No 159 136 204 145 6.1 
 
  
 S. 
No 
NAME AGE SEX DIABETES HYPERTENSION RBS FBS PPBS UREA CREATININE 
51. Balayan 52 M Yes No 178 152 210 114 3.0 
52. Appadurai 60 M Yes No 205 146 243 130 5.1 
53. Raman 36 M Yes No 152 131 192 96 3.1 
54. Vivek 22 M Yes No 170 154 243 152 7.0 
55. Maharajan 55 M Yes No 190 162 258 128 4.8 
56. Chandran 55 M Yes No 162 180 241 120 4.2 
57. Palani 45 M Yes No 146 135 198 126 5.0 
58. Soundarrajan 70 M Yes No 167 144 219 133 5.4 
59. Victor 35 M Yes No 142 136 202 92 3.0 
60. Kaliyamoorthi 65 M Yes No 156 143 218 120 5.0 
 
S. 
No 
NAME eGFR 
Urine 
Albumin 
Urine 
Deposits 
Urine 
Sugar 
Serum 
Sodium 
Serum 
Potassium 
HB 
Vitamin 
D 
ECG 
1. Dhanalakshmi 23.3 + 0 – 2 Nil 136 4.8 8.8 21.7 LVH 
2. Thamaraiselvi 17.8 +++ 0 – 2 ++ 130 4.9 8.0 19.1 LVH 
3. Vembayee 16.5 Nil Nil Nil 123 3.6 9.8 15.6 NSR, WNL 
4. Sigappayee 15.6 ++++ Nil ++ 132 5.7 8.8 22.4 NSR, WNL 
5. Vijaya 18 + Nil Nil 126 5.1 6.1 36.2 LVH 
6. Parvathi 18.4 Nil Nil Nil 134 4.3 7.2 28.4 NSR, WNL 
7. Nallambal 24 Nil Nil Nil 142 4.0 10.2 12.6 NSR, WNL 
8. Poongodi 22.2 +++ Nil +++ 142 4.2 9.1 13.8 LVH 
9. Prema 16.7 + 0 – 2 Nil 138 4.3 7.2 20.4 NSR, WNL 
10. Azhagammal 15.8 ++ Nil Nil 131 3.8 4.6 26.5 NSR, WNL 
 
  
 S. 
No 
NAME eGFR 
Urine 
Albumin 
Urine 
Deposits 
Urine 
Sugar 
Serum 
Sodium 
Serum 
Potassium 
HB 
Vitamin 
D 
ECG 
11. Anjammal 15.2 ++ Nil Nil 142 3.5 6.7 14.2 NSR, WNL 
12. Manimegalai 15.3 + Nil Nil 137 3.4 11.2 23.1 NSR, WNL 
13. Padma  15.6 + Nil Nil 140 3.9 6.2 16.4 NSR, WNL 
14. Russiya 30.8 Nil 0 – 2 Nil 144 4.2 13.6 18.9 NSR, WNL 
15. Malliga 33.7 Nil Nil Nil 143 4.2 13.0 11.3 LVH+ 
16. Kumarasamy 22.5 + Nil Nil 140 4.0 8.0 33.33 NSR, WNL 
17. Azhagar 31.0 Nil Nil Nil 141 4.3 10.4 36.03. NSR, WNL 
18. Tamilarasu 16.2 Nil Nil Nil 136 3.9 8.4 32.68 NSR, WNL 
19. Murugesan 16.6 Nil 0–2 Puscells Nil 133 4.9 7.8 11.24 NSR, WNL 
20. Shanmugam 15.4 Ni Nil Nil 140 4.6 7.8 11.24 NSR, WNL 
 
  
 S. 
No 
NAME eGFR 
Urine 
Albumin 
Urine 
Deposits 
Urine 
Sugar 
Serum 
Sodium 
Serum 
Potassium 
HB 
Vitamin 
D 
ECG 
21. Thangadurai 19.8 Nil Nil Nil 129 3.7 8.8 13.33 NSR, WNL 
22. Srinivasan 15.9 Nil Nil Nil 123 5.2 7.6 18.21 NSR, WNL 
23 Kennedy 18.9 + Nil Nil 140 4.3 11.4 21.26 NSR, WNL 
24 Krishnamoorthi 15.2 + Nil Nil 138 5.2 6.2 19.2 NSR, WNL 
25. Singarayar 16.9 Nil Nil Nil 120 4.2 9.6 18.4 NSR, WNL 
26. Rajendran 17.2 Nil Nil Nil 131 3.6 8.8 13.4 NSR, WNL 
27. Elangovan 42 Nil Nil Nil 132 4.3 13.8 30.9 NSR, WNL 
28. Pakkirisamy 18.6 Nil Nil Nil 127 3.0 4.6 19.9 NSR, WNL 
29. Settu 16.6 Nil Nil Nil 132 6.0 6.3 24.9 NSR, WNL 
30. Manikandan 36.9 Nil Nil Nil 140 4.2 13.2 33.42 NSR, WNL 
 
  
 S. 
No 
NAME eGFR 
Urine 
Albumin 
Urine 
Deposits 
Urine 
Sugar 
Serum 
Sodium 
Serum 
Potassium 
HB 
Vitamin 
D 
ECG 
31. Sundarrajan 17.0 Nil Nil Nil 117 2.7 7.0 25.6 LVH 
32. Punniyamoorthi 39.2 + Nil Nil 140 4.5 14.2 23.43 NSR, WNL 
33. Madhiyazhagan 19.2 + 0–2 Puscells Nil 128 3.9 10.4 19.21 LVH(+) 
34. Kamaldeen 18.1 ++ 0–2 Puscells Nil 114 3.5 8.8 12.29 LVH(+) 
35. Yesupillai 15.8 ++ Nil Nil 118 3.6 8.6 16.48 LVH(+) 
36. Arumugam 17.3 Nil Nil Nil 137 6.6 6.6 11.29 LVH(+) 
37. Arivazhagan 15.2 Nil 0–2 deposit Nil 140 4.7 10.8 15.64 LVH 
38. Jothi 18.9 ++ Nil Nil 120 4.9 6.6 19.21 LVH 
39. Vijay 18.9 Nil Nil Nil 139 5.4 10 13.26 LVH 
40. Ramalingam 27.1 ++ 0–2 deposit Nil 115 3.9 8.2 19.26 LVH 
 
  
 S. 
No 
NAME eGFR 
Urine 
Albumin 
Urine 
Deposits 
Urine 
Sugar 
Serum 
Sodium 
Serum 
Potassium 
HB 
Vitamin 
D 
ECG 
41. Govintharaj 19.3 Nil Nil Nil 136 5.1 10.5 18.7 LVH 
42. Ramachandran 16.2 Nil Nil Nil 142 6.5 9 38.0 NSR,WNL 
43. Ragamathullah 36.4 Nil Nil Nil 145 4.2 12.0 42.4 NSR,WNL 
44. Sowrinayagam 20.8 + 0–2 deposit Nil 136 43 9.2 13.52 LVH 
45 Jayakumar 17.1 Nil Nil Nil 148 4.0 7.9 9.28 LVH 
46 Kumaresan 22.6 Nil 0–2 deposit ++ 153 2.4 8.4 19.26 NSR,WNL 
47. Ramesh 24.2. +++ Nil +++ 137 4.7 9.0 13.22 NSR,WNL 
48. Perumal 18.4 ++ Nil +++ 133 5.5 8.2 17.26 
↓‘T’ wave 
in 
II, IIІ, avf 
49. Annadurai 26.3 ++++ 0–2 Puscells ++ 130 48 9.2 24.5 NSR,WNL 
50. Saminathan 15.7 ++++ Nil ++ 141 4.2 5.3 14.1 NSR,WNL 
 
  
 S. 
No 
NAME eGFR 
Urine 
Albumin 
Urine 
Deposits 
Urine 
Sugar 
Serum 
Sodium 
Serum 
Potassium 
HB 
Vitamin 
D 
ECG 
51. Balayan 22.4 Nil Nil ++ 142 3.8 10.1 20.42 NSR,WNL 
52. Appadurai 16.3 ++ 0-2 Puscells + 133 4.4 5.6 11.42 NSR,WNL 
53. Raman 34.9 ++ Nil + 148 40 9.8 23.42 NSR,WNL 
54. Vivek 15.2 +++ Nil ++ 142 4.6 6.2 17.29 NSR,WNL 
55. Maharajan 15.9 +++ Nil ++ 130 3.8 7.8 14.33 NSR,WNL 
56. Chandran 18.2 +++ Nil ++ 142 4.6 6.2 17.29 NSR,WNL 
57. Palani 17.1 +++ Nil + 145 3.9 8.2 12.56 NSR,WNL 
58. Soundarrajan 15.2 +++ 0-2 Puscells ++ 126 4.2 7.2 9.36 
‘Q’ wave in 
II, IIІ, avf 
V5, V6 
59. Victor 31.5 ++ Nil ++ 140 4.5 11.8 28.32 NSR,WNL 
60. Kaliyamoorthi 17.6 ++ Nil + 145 3.7 8.9 13.75 NSR,WNL 
 
S. 
No 
NAME USG Abdomen 
Stage of 
CKD 
BP IP/OP NO 
1. Dhanalakshmi RK 70x34mm - LK 71x37mm 
B/L Contracted kidney 
4 160/90 OP NO:126643 
2. Thamaraiselvi B/L Contracted kidney 4 150-90 IP NO: 21011 
3. Vembayee B/L Contracted kidney 4 110/80 IP NO: 23760 
4. Sigappayee 
RK 94x37 mm 
LK 80x33 mm 
B/L Type II RPD 
4 110/70 IP NO: 25749 
5. Vijaya 
RK 77x36 mm 
LK 80x92 mm 
B/L Type II RPD 
4 180/90 OP NO: 78457 
6. Parvathi B/L Contracted kidney 4 100/70 OP NP: 56442 
7. Nallambal B/L Contracted kidney 4 120/70 IP NO: 38705 
8. Poongodi B/L Contracted kidney 4 160/70 IP NO: 37081 
9. Prema B/L Contracted kidney 4 140/80 IP NO:38354 
10. Azhagammal B/L Contracted kidney 4 110/70 IP NO: 37514 
  
S. 
No 
NAME USG Abdomen 
Stage of 
CKD 
BP IP/OP NO 
11. Anjammal B/L Type II RPD 4 120/82 IP NO: 38212 
12. Manimegalai Single Kidney 
LK contracted Kidney 
4 114/80 OP NO: 152776 
13. Padma  B/L Contracted kidney 4 120/70 IP NO: 39442 
14. Russiya B/L Contracted kidney 3 110/70 OP NO: 94336 
15. Malliga B/L Contracted kidney 3 150/80 OP NO: 2638/15 
16. Kumarasamy RK 7.7x3.1cm 
LK 7.1x2.8cm 
4 120/70 IP NO: 20549 
17. Azhagar 
RK 62x30mm 
LK 65x30mm  
B/L Contracted kidney 
3 110/70 OP NO: 148841 
18. Tamilarasu B/L Contracted kidney 3 120/80 OP NO: 74882 
19. Murugesan RK 58x28mm 
LK 64x30mm 
4 100/70 IP NO: 19522 
20. Shanmugam 
RK 81x34mm 
LK 81x37mm  
B/L Contracted kidney 
4 106/80 IP NO: 27190 
  
S. 
No 
NAME USG Abdomen 
Stage of 
CKD 
BP IP/OP NO 
21. Thangadurai 
B/L Contracted kidney 
1 120/76 IP NO: 28645 
22. Srinivasan 
RK 66x24mm 
LK 81x37mm  
B/L Contracted kidney 
4 110/80 IP NO: 299O8 
23 Kennedy 
RK 69x30mm 
LK 61x30mm  
B/L Contracted kidney 
4 120/76 IP NO: 28576 
24 Krishnamoorthi B/L Contracted kidney 4 110/72 IP NO: 39883 
25. Singarayar 
RK 64x30mm 
LK 69x35mm  
B/L Contracted kidney 
4 120/70 IP NO: 26339 
26. Rajendran B/L Contracted kidney 4 110/60 IP NO: 38570 
27. Elangovan 
RK 85x30mm 
LK 78x32mm  
B/L Contracted kidney 
3 120/80 IP NO: 38536 
28. Pakkirisamy 
RK 8.1x3.4mm 
LK 7.6x3.0mm  
B/L Contracted kidney 
4 170/70 IP NO: 39943 
29. Settu 
RK 7.2x30mm 
LK 74x31mm  
B/L Contracted kidney 
4 110/80 OP NP:168442 
S. 
No 
NAME USG Abdomen 
Stage of 
CKD 
BP 
IP/OP NO 
30. Manikandan 
RK 80x32mm 
LK 72x33mm 
B/C Contracted kidney 
3 110/80 IP NO:44331 
31. Sundarrajan 
RK 64x30mm 
LK 66x32mm 
B/C Contracted kidney 
4 160/80 IP NO: 20403 
32. Punniyamoorthi 
RK 78x34mm 
LK 80x30mm 
B/C Contracted kidney 
3 140/80 OP NO: 63384 
33. Madhiyazhagan 
RK 74x34mm 
LK 80x32mm 
B/C Contracted kidney 
4 150/86 IP NO:25331 
34. Kamaldeen 
RK 86x30mm 
LK 82x32mm 
B/C Contracted kidney 
4 170/84 IP NO: 25300 
35. Yesupillai RK 74x28mm 
LK 68x26mm 
4 164/90 IP NO: 26390 
36. Arumugam RK 64×30mm    LK 70×32mm 4 180/90 OP NO: 17339 
37. Arivazhagan 
RK 80x30mm 
LK – not  visualized  
B/C Contracted kidney 
4 170/100 IP NO:23641 
38. Jothi RK 65x28mm 
LK 68x30mm 
4 160/110 IP NO: 26751 
S. 
No 
NAME USG Abdomen 
Stage of 
CKD 
BP 
IP/OP NO 
39. Vijay RK 81x33mm 
LK 8.2x36mm 
4 180/100 OP NO: 163329 
40. Ramalingam 
RK 73x39mm 
LK 70x38mm 
4 140/80 IP NO:31291 
41. Govintharaj RK 71x32mm 
LK 75x30mm 
4 150/80 OP NO: 73398 
42. Ramachandran RK 76x30mm 
LK 74x30mm 
4 130/90 IP NO: 39641 
43. Ragamathullah RK 75x33mm 
LK 78x34mm 
3 140/80 OP NO: 119342 
44. Sowrinayagam RK 62x32mm 
LK 65x30mm 
4 160/70 OP NO: 3722 
45 Jayakumar RK 60x28mm 
LK 63x30mm 
4 156/110 IP NO: 39826 
46 Kumaresan RK 70x30mm 
LK 74x31mm 
4 120/70 IP NO: 20490 
47. Ramesh RK 60x30mm 
LK 84x34mm 
4 110/70 IP NO: 31282 
48. Perumal RK 70x28mm 
LK 65x30mm 
4 100/60 OP NO: 9942 
49. Annadurai RK 70x30mm 
LK 65x28mm 
4 110/80 OP NO: 19447 
50. Saminathan RK 62x30mm 
LK 65x28mm 
4 100/76 IP NO: 40021 
 S. 
No 
NAME USG Abdomen 
Stage of 
CKD 
BP 
IP/OP NO 
51. Balayan RK 75x32mm 
LK 70x30mm 
4 120/76 IP NO: 38658 
52. Appadurai RK 62x35mm 
LK 60x30mm 
4 110/70 IP NO: 40762 
53. Raman RK 76x34mm 
LK 78x40mm 
3 120/78 OP NO: 169438 
54. Vivek RK 92x45mm 
LK 96x48mm 
4 110/80 IP NO: 44196 
55. Maharajan RK 90x41mm 
LK 92x40mm 
4 120/78 IP NO:43917 
56. Chandran RK 78x32mm 
LK 68x30mm 
4 110/60 IP NO: 44175 
57. Palani RK 75x30mm 
LK 80x36mm 
4 120/74 IP NO: 42317 
58. Soundarrajan RK 62x28mm 
LK 66x30mm 
4 110/76 IP NO: 41315 
59. Victor 
RK 92x41mm 
LK 90x40mm 
 
3 110/80 OP NO: 58852 
60. Kaliyamoorthi RK 75x30mm 
LK 68x32mm 
4 120/70 OP NO: 137742 
 
